Can a Two-Pronged pill outsmart stubborn leukemia?
NCT ID NCT07137637
First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This early-stage trial is testing an experimental oral drug, HPB-092, in people whose acute myeloid leukemia (AML) has returned or not responded to standard treatments. The drug is designed to block two proteins, FLT3 and IRAK4, that help leukemia cells grow and survive. The study aims to find a safe dose and check for early signs that the drug might shrink or control the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental oral drug called HPB-092 that blocks two cancer-driving proteins (FLT3 and IRAK4)
- What this could lead to
- If successful, HPB-092 could offer a new treatment option for patients with hard-to-treat AML that has returned or not responded to prior therapy.
- What could go wrong
- This is an early phase 1 trial with only 60 participants, so safety and the right dose are still being determined. It is too early to know if the drug will work or have serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA (RR-AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology and Blood Diseases Hospital, Tianjin, China
RECRUITINGTianjin, 300020, China
Contact Email: •••••@•••••